The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1183 March 15, 2007 Number 11
NextNext

Another Look at Imatinib Mesylate

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Strebhardt, K.
-PubMed Citation
To the Editor: Strebhardt and Ullrich (Dec. 7 issue)1 discuss the study by Kerkelä et al., which suggested that imatinib is cardiotoxic.2 However, there are controversial data on the role of imatinib on cardiac function that are not discussed. We published data showing that a reduced dose of imatinib (30 mg per kilogram of body weight per day) was cardioprotective in hypertensive rats.3 Kerkelä et al. examined various doses of imatinib but showed a loss of cardiac function only at higher doses than those used in other studies.3,4,5 Furthermore, clinical evidence of the cardiotoxicity of imatinib is circumstantial. Only 3 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.